Document is current
Any future updates will be listed below
-
Authors
Han, Kai https://orcid.org/0000-0001-5370-4296
Xie, Fang
Animasahun, Olamide https://orcid.org/0000-0002-4032-3619
Nenwani, Minal
Kitamoto, Sho
Kim, Yeji
Phoo, May Thazin https://orcid.org/0000-0002-9411-621X
Xu, Jin
Wuchu, Fulei https://orcid.org/0000-0002-7772-7449
Omoloja, Kehinde https://orcid.org/0009-0001-6446-984X
Achreja, Abhinav https://orcid.org/0000-0002-1773-6490
Choppara, Srinadh
Li, Zhaoheng
Gong, Wang
Cho, Young Seok https://orcid.org/0000-0003-1338-3170
Dobson, Hannah https://orcid.org/0000-0003-1246-880X
Ahn, Jinsung
Zhou, Xingwu
Huang, Xuehui
An, Xinran
Kim, Alexander
Xu, Yao
Wu, Qi https://orcid.org/0000-0002-2550-3769
Lee, Soo-Hong
O’Konek, Jessica J. https://orcid.org/0000-0002-1455-0586
Xie, Yuying
Lei, Yu Leo
Kamada, Nobuhiko
Nagrath, Deepak https://orcid.org/0000-0002-8999-2282
Moon, James J. https://orcid.org/0000-0003-2238-2372
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125087)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R01DE030691, R01DE026728, R01DE031951, U01DE033330)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS122536)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA210273, R01CA271369, R01CA227622, R01CA222251, R01CA204969, P30CA046592)
- License Information
-
More Information
Article History
Received: 4 December 2022
Accepted: 30 April 2024
First Online: 8 July 2024
Competing interests
: Patent applications for inulin-gel-based treatment for allergies and other disorders have been filed in the USA, Europe, Japan, South Korea, China, Australia and Canada (US20230346826, WO2022066825, US20220347294 and WO2021061789), with J.J.M., K.H., F.X., J.X., X.H. and X.Z. as inventors. J.J.M. declares financial interests for board membership, as a paid consultant, for research funding, and/or as an equity holder in EVOQ Therapeutics and Saros Therapeutics. The University of Michigan has a financial interest in EVOQ Therapeutics, Inc. The other authors declare no competing interests.
